Purpose: The premise for the study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have been shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. This phase II study evaluated the antitumor activity of TPT administered at its highest possible solid tumor dose with G-CSF in patients with fluoropyrimdinerefractory advanced colorectal carcinoma. The study also sought to identify pharmacodynamic (PD) determinants of both activity and toxicity.
Purpose: The premise for the study was that topotecan (TPT) resistance in preclinical studies is associated with low level expression of the p-glycoprotein (Pgp) multi-drug transporter conferred by the multi-drug resistant (MDR) phenotype, which might be overcome in clinical practice by administering moderately (2.3-fold) higher doses of TPT that have been shown to be feasible with granulocyte colony-stimulating factor (G-CSF) support. This phase II study evaluated the antitumor activity of TPT administered at its highest possible solid tumor dose with G-CSF in patients with fluoropyrimdinerefractory advanced colorectal carcinoma. The study also sought to identify pharmacodynamic (PD) determinants of both activity and toxicity.
Patients and methods: TPT was administered as a 30-minute infusion daily for five days every three weeks at a dose of 3.5 mg/m 2 /day to patients with advanced colorectal carcinoma who developed progressive disease either during treatment with fluoropyrimidine-based chemotherapy for advanced disease or within six months after receiving fluoropyrimdinebased adjuvant chemotherapy. This dose of TPT was previously determined to be the maximal tolerated dose (MTD) with G-CSF support in a phase I study involving solid tumor patients with similar risk factors for myelosuppression. Plasma sampling was performed during course 1 to characterize the pharmacokinetic (PK) and PD behavior of TPT.
Results: Seventeen patients who received 89 courses of TPT and G-CSF were evaluable for toxicity; 16 patients were evaluable for anti-tumor response. Toxicity, particularly myelosuppression, was substantial. At the 3.5 mg/m 2 /day dose level, absolute neutrophil counts (ANC) were less than 500/ul for longer than five days in 17% of courses involving seven of 17 (41%) patients. Severe neutropenia associated with fever occurred in 12.3% of courses; and platelet counts below 25,000/ul were noted in 26.9% of courses. These toxicities resulted in dose reductions in seven of 17 (41%) patients. Nevertheless, 90% of the planned total dose of TPT was administered. No major responses were observed, though minor activity was noted in several patients. Both the median time to progression and the median survival time were short -2.5 and four months, respectively. Although interindividual variability in the disposition of total TPT was observed, the lack of objective responses precluded PD assessments related to disease activity. Total TPT exposure was significantly higher than drug exposure achieved in similar patients at an identical dose in a previous phase I study of TPT and G-CSF, which may explain why more severe myelosuppressive effects occurred in the present study. There were no PD relationships evident between relevant PK parameters and the percent decrements in platelets and ANCs during course 1, although patients with severe toxic effects (ANC below 500/ul for more than five days and/or platelets < 25,000/nl) had higher drug exposure than patients with less severe toxicity (P < 0.018 and P -0.09, respectively).
Conclusions: Based on these results, the true response rate of TPT at its solid tumor MTD with G-CSF support is unlikely to approach 20%. Although a response rate of less than 20%
Introduction
The semi-synthetic hydrophilic camptothecin (CPT) analog topotecan (TPT; Hycamptin®; 9-dimethyl-aminomethyl-10-hydroxycamptothecin) that targets the nuclear enzyme topoisomerase I (topo I), has demonstrated broad antitumor activity in preclinical evaluations, as well as in phase I-III clinical trials, including leukemias, gliomas, sarcomas, and ovarian and small cell lung carcinomas [1] [2] [3] [4] [5] [6] [7] . The demonstration that colon cancer contains higher levels of topoisomerase I than adjacent normal tissue, suggesting that it may be more amenable to selective targeting by topoisomerase I inhibitors, and encouraging preclinical activity with TPT in murine colon carcinomas 38 and 51 and in human colon carcinoma xenografts HT-29 and SW-48 sup-ported a rationale to perform disease-directed evaluations of TPT in patients with colorectal carcinoma [1] [2] [3] 8] . However, TPT on several schedules including a 30-minute infusion daily for five days schedule, the most commonly used schedule, and a prolonged 21-day infusion schedule has demonstrated a low level of activity in colorectal carcinoma and other gastrointestinal malignancies [9] [10] [11] [12] . In contrast, the water soluble hydrophilic camptothecin analogue irinotecan (CPT-11) has received regulatory approval worldwide for treatment of patients with advanced colorectal cancer that is refractory to the fluoropyrimidines [13] [14] [15] [16] [17] , and several responses were noted in patients with colorectal and other gastrointestinal cancers in phase I-II trials of the parent compound camptothecin (CPT) that were performed several decades ago [1] .
Several mechanisms of drug resistance are shared by CPT and CPT analogs. P-glycoprotein (Pgp) overexpression associated with the multi-drug resistance (MDR) phenotype has been demonstrated to confer a low level of cross-resistance to several CPT analogs in vitro including TPT, but neither CPT or the active irinotecan metabolite SN-38 appear to be efficient substrates for Pgp [18] [19] [20] [21] . A low level of resistance to TPT relative to the parent drug CPT has been observed with certain Pgp-expressing cell lines in vivo [31] , and it is possible that this mechanism may account, in part, for the poor activity achieved with conventional TPT doses in colorectal and other cancers derived from tissues that constitutively overexpress the Pgp multi-drug transporter [18] [19] [20] [21] . Since TPT's principal dose-limiting toxicity on all schedules, neutropenia, is brief and noncumulative, the feasibility of using hematopoietic colony-stimulating factor support to enable dose escalation of TPT, potentially to overcome low-level drug resistance conferred by MDR, has been evaluated. In a prior phase I study, treatment with granulocyte colony-stimulating factor (G-CSF) starting on day 6 after five daily 30-minute infusions of TPT enabled TPT doses to be escalated from 1.5 to 3.5 mg/m 2 /day in minimally-pretreated solid tumor patients, with severe neutropenia and thrombocytopenia precluding further dose escalation [22] . This phase II study was performed to determine if high doses of TPT as a 30-minute infusion given daily for five days every three weeks with G-CSF support produced a meaningful degree of anti-tumor activity in patients with colorectal cancer whose disease was refractory or recurred following fluorpyrimidine-based therapy and to further characterize the toxicity of this regimen.
Patients and methods

Eligibility
Only patients with metastatic, histologically-confirmed colorectal cancer were considered candidates for this study. Patients must have developed progressive disease while receiving fluoropyrimidine-based chemotherapy for advanced disease or within six months after receiving fluoropyrimidine-based adjuvant chemotherapy. Patients may have received adjuvant chemotherapy in addition to one fluoropyrimdinebased regimen for advanced disease. Patients were ineligible if they had received wide-field radiation to the pelvis or to more than 25% of bone marrow-bearing bones or any nitrosorurea or mitomycin-C. Eligibility criteria also included: 1) age > 18 years; 2) Eastern Cooperative Oncology (ECOG) performance status ^ 2 (ambulatory and capable of self-care) and an expected survival ^ three months; 3) recovery from any significant toxicity or morbidity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy. Three weeks must have elapsed between the onset of therapy and prior limited field radiotherapy or chemotherapy. Patients had to have at least one bidimensionally measurable lesion with both dimensions greater than one centimeter that has not been treated with radiotherapy; 5) adequate hematopoietic (absolute neutrophil count (ANC) > 1500/ul, platelets ^ 100,000/ul), hepatic (total bilirubin =£2.0 mg/dl) and renal (creatinine ^ 1.5 mg/dl) function; 6) no other coexisting medical problem of sufficient severity to prevent full compliance with the study; and 7) no history of hemorrhagic cystitis and less than five RBCs per high-power filed in urine. All patients gave informed written consent before treatment.
Dosage and drug administration
The starting dose of TPT was 3.5 mg/m 2 /day administered as a 30-minute infusion daily for five consecutive days, which was the recommended phase II dose achieved in the previous phase I study of TPT and G-CSF in comparable patients with respect to prior myelosuppressive therapy [22] . Subsequent courses were administered at a minimum interval of 22 days as long as patients continued to fulfill the initial eligibility requirements. Treatment with G-CSF 5 ug/kg/day subcutaneously was begun 24 hours after the fifth dose of TPT on day 6 and was continued until the ANC was at least 10,000/ul. Patients kept a log detailing G-CSF administration. Successive TPT dose reductions were performed to 3.5, 3.0, and 2.5 mg/m 2 in patients who experienced: 1) ANC <500/ul for longer than five days; 2) platelets < 25,000/ul for longer than three days; 3) grade 3 or 4 nonhematologic toxicity (except for nausea and/or vomiting in the absence of optimal antiemetics as prophylaxis and management; or 4) treatment delays due to unresolved toxicity lasting longer than seven days. Dose escalation to 4.2 mg/m 2 was to be permitted if patients did not experience the following toxicities during a previous course: 1) ANC < 500/ul; 2) platelets <50,000/ul; 3) nonhematologic toxicity > grade 1 except nausea and/or vomiting in the absence of optimal antiemetic therapy.
TPT was supplied by the Division of Cancer Treatment, Diagnosis, and Centers, NCI (Bethesda, MD) in vials containing a lyophilized mixture of 5 mg of TPT and 100 mg mannitol. The pH was previously adjusted to 3 to 4 with hydrochloric acid and sodium hydroxide. TPT was reconstituted with 2 ml sterile water. The total daily dose of TPT was diluted with 50 ml of 5% dextrose solution and administered over 30 minutes. Recombinant methionyl human G-CSF (Amgen, Inc; Thousand Oaks, CA) was supplied as a sterile solution with 0.3 mg/ ml in a 2-ml ampule in sterile water by Amgen Inc.
Pretreatment and follow-up studies
Histories, physical examinations, and routine laboratory studies were performed before treatment. Electrolytes, chemistries, renal and liver function tests, prothrombin time, and urinalysis were performed weekly. Complete blood counts and differential white blood cell counts were obtained three times weekly until an ANC > 10,000/ul was achieved following the ANC nadir. Toxicities were evaluated according to the NCI Common Toxicity Criteria.
Response assessment
Formal tumor measurements were performed after every two courses and patients were able to continue treatment if they did not develop progressive disease or unacceptable toxicities. A complete response was defined as the disappearance of all disease on two measurements separated by a minimum of three weeks and a partial response required a greater than 50% decrease in the sum of the products of the dimensional measurements of all measurable lesions documented by measurements separated by at least three weeks. Patients were considered evaluable for determination of anti-tumor response if they received at least two complete courses of TPT. Patients with objective evidence of disease progression during TPT were also considered evaluable for response. Patients who were taken off study before two courses for reasons other than disease progression (e.g., toxicity, patient request) were not considered evaluable for determination of anti-tumor activity, though they were considered in an overall intentto-treat analysis. If none of the first 14 evaluable patients responded, further accrual was to be terminated in view of a 5% probability of incorrectly rejecting the treatment with a true response rate of 20%. If at least one patient in the first 14 evaluable patients responded, an additional 11 patients were to be treated to estimate the true activity with a standard error of no greater than 10%.
Plasma sampling and assay
To study the pharmacokinetic (PK) behavior of high doses of TPT, whole blood samples in heparmzed tubes were obtained from indwelling venous catheters placed in the arm contralateral to the drug infusion. Samples were collected immediately before the infusion, 15 min during the infusion, immediately before the end of the infusion, then at 15, 20, and 30 min, and four, six, and 24 hours after the end of infusion on day 1 of course 1. Samples were centrifuged and plasma was frozen at -70 °C until assayed.
Specimens processing, extraction, and high-performance liquid chromatography for quantitation of total TPT (lactone plus hydroxy acid forms) were performed using a method described previously [23] . Retention times and peak areas were calculated using the Nelson 3000 chromographic data system (P.E. Nelson, Cupertino, CA). Drug concentrations were calculated from calibration curves made with pretreatment plasma of each subject at TPT concentrations that ranged from 5-500 r|M. Calibration curves were linear, with correlation coefficients > 0.997. The coefficents for intraday reproducibility were 3% to 14% and 2% to 8% at plasma concentrations of 5 and 500 r|M, respectively. The coefficients for interday reproducibility, as assessed by evaluating slopes from five calibration curves assayed in a two-week period, was < 20%.
Pharmacokinetic analysis
Atwo-compartment model was fitted to individual total TPT plasma concentrations using a MAP-Bayesian algorithm as implemented in Adapt II (University of Southern California, Los Angeles, CA). Bayesian priors were derived from a previous published study of TPT 2.0-4.2 mg/m 2 /day for five days plus G-CSF [22, 23] . Estimated primary parameters included the volume of distribution for the central compartment (V c ), elimination rate constant (kj), and intercompartment constants (kc P and kpc). Calculated PK parameters included the AUC from zero to infinity, systemic clearance (Cl s ), alpha and beta half-lives (t 1/2 5 and t 1/2 p), and the volume of distribution at steady-state (V dss ). Maximal plasma concentration (C nax ) was determined from the fitted curve. 
Results
General
Seventeen patients with metastatic colorectal carcinoma were treated with 89 courses of high-dose TPT with G-CSF support in this phase II study. Patient characteristics are displayed in Table 1 . All patients had received prior treatment with 5-fluorouracil and leucovorin for metastatic disease and /or recurred within six months after receiving 5-fluorouracil-based therapy in the adjuvant setting. Two patients were previously treated with limited-field radiation therapy. The median number of courses received was 3 (range 1-18). Three patients were treated with only one course due to the development of fungal esophagitis and fungemia (one patient) and decrements in their performance status which were subsequently attributed to progressive disease. The numbers of patients and courses as a function of TPT dose administered are shown in Table 2 . Seven of 14 patients (50%) who received at least two courses required at least one reduction of the TPT dose to 3.0 mg/ m 2 /day because of severe myelosuppression during the previous course. Three patients required a second TPT dose reduction to 2.5 mg/m 2 /day. No patients were eligible for dose escalation. With respect to all courses, 90% of the planned total dose of TPT was administered, Table 2 . Patients and courses as a function of dose level.
Statistical analysis
PK parameters were summarized using descriptive statistics including means, standard deviations (SD), and ranges. The Wilcoxan Rank Sum test was used to compare values for systemic exposure (C maJ i) and AUC between those patients who experienced severe toxic effects (platelets <25,000/ul and ANC <500/ul for longer than five days) and those who did not experience severe toxicities during course 1. a Worst grade of toxicity experienced per patient treated at each dose level. The following classifications are mutually exclusive: ANC < 500/ul five days and ANC < 500/ul > five days for neutropenia; and platelets <50,000/ul and 5=25,000/^1, <25,000/ul, <25,000/ul > three days. whereas 86% of the planned dose of TPT was administered in the first four courses.
Anti-tumor activity
No major responses were noted during the study. Although disease remained at least stable for longer than six months in four patients including stable disease for at least 12 months in two patients, the median time to progression was 2.5 months and the median survival was four months for all patients. One of these patients included a 69-year-old male with metastatic colorectal carcinoma to the liver who experienced a 38% reduction in the size of his liver metastases along with a slight reduction in a mildly elevated CEA from 24 to 17 rig/ml that lasted 15 months. Decrements in CEA (389-242 rig/ml; 49-23 r|g/ml; and 131-68 rig/ml) without objective reduction in the size of measurable disease were observed in three other individuals.
Toxicity Hematologic
This phase II study of TPT with G-CSF support was designed to evaluate the activity of TPT at its highest level of tolerability in this patient population, which resulted in considerable myelosuppression as shown in Table 3 . At the 3.5 mg/m 2 /day TPT dose level, ANC nadirs decreased to below 500/ul in all patients at some time during their treatment. Sixty-two percent of all courses were associated with an ANC nadir below 500/ ul at this dose level; however, this degree of neutropenia was tolerated well in most courses. ANC nadirs were below 500/ul for more than five days in eight of 47 courses (17%) involving seven of 17 (41%) patients. Fever associated with neutropenia (ANC < 1000/ul) occurred during 12.3% of courses involving 41% of patients. Although ANC below 500/ul were also experienced frequently by patients treated with TPT at the 3.0 and 2.5 mg/m 2 dose levels, the percentages of courses associated with either an ANC < 500/ul for more than five days or neutropenia associated with fever ranged 5%-10%.
Most patients experienced severe (platelets < 25,000/ ul) thrombocytopenia, albeit brief (< three days), at all dose levels, as shown in Table 3 . More specifically, platelet counts decreased below 25,000/ul in nine of 47 (19%) courses at the 3.5 mg/m 2 /day dose level, with this level of thrombocytopenia lasting longer than three days in three (6%) courses. Severe thrombocytopenia remained problematic at the 3.0 and 2.5 mg/m 2 dose levels. Anemia (grade 3) requiring transfusions of red blood cells was also prominent following high-dose TPT and G-CSF, occurring during 19% of courses.
Nonhematologic
The most common nonhematological toxicities as a function of total courses are listed in Table 4 . In contrast to studies of TPT performed at conventional doses (i.e., 1.5 mg/m 2 /day for five days every three weeks), nausea and/or vomiting were common in the peritreatment period, occurring in 41 of 89 (46%) courses, with severe (grade 3) manifestations occurring in three courses at the 3.5 mg/m 2 dose level. Similarly, the incidence of skin manifestations appeared to be more common than in studies of TPT at lower doses with grade 1 or 2 rashes developing in eight patients during 29 courses [1, 7-19, 34, 36-40]. The onset of the rash, which was characterized by a diffuse macular-papular eruption on the trunk and face and occasionally on the extremities, typically occurred on days 3-5. The intensity of the rash was greatest on days 5-8, with complete resolution usually by days 10-15. Six patients also complained of a generalized headache during the peritreatment period in 21 (23.6%) courses, which was severe in two patients during two courses each at the 3.5 and 3.0 mg/m 2 /day dose levels. Other nonhematological effects that were mild to modest in severity included diarrhea, mucositis, and fever.
Pharmacokinetic andpharmacodynamic studies
Seventeen patients had PK sampling performed during course 1. Plasma concentration data for total TPT from 15 of 17 patients were well fit by a two-compartment model using the MAP Bayesian approach. Unsuccessful attempts were characterized by extremely large (> 100%) values for the coefficients of variation of the parameter values. The means (SD) and ranges of pertinent PK parameters are summarized in Table 5 and the observed data and fitted plasma disposition data from a representative subject are displayed in Figure 1 . Overall, there was considerable interpatient variability in drug disposition. C max values averaged 251 r|M (range 194-373), whereas mean values for t 1 / 2 s and Cl were 4.1 hour (range 2.5-6.2) and 212 ml/nr (range 76-319). respectively. The relationships between pertinent PK parameters (C max and AUC) and indices reflecting the severity of both neutropenia and thrombocytopenia during course 1 were evaluated. No relationships were evident between these PK parameters and percent decreases in both ANCs and platelets in these patients receiving G-CSF. However, AUC values were higher in patients experiencing dose-limiting hematological toxicities (Figure 2a  and b) . Patients who experienced ANC nadirs < 500/ul for more than five days had significantly higher AUC values than patients who had less severe neutropenia or ANC nadirs < 500/ul for shorter periods (median AUCs, 44 versus 28, P = 0.018). Similarly, patients who experienced grade 4 thrombocytopenia (platelets < 25,000/ul) during course 1 had higher AUC values than patients who did experience this grade of toxicity, although only three patients experienced grade 4 thrombocytopenia during course 1 (n = 3) and the difference approached statistical significance (P -0.096).
Conclusions
The differences in the clinical anti-tumor spectra of the various topoisomerase I-targeting agents are intriguing. For treatment of patients with colorectal carcinoma, despite encouraging activity for TPT and irinotecan in preclinical models [1] [2] [3] , only irinotecan has demonstrated major activity. The response rates for irinotecan are reported as 15%-23% and 18.3%-32% in previously untreated and fluoropyrimidine-refractory patients with advanced disease, whereas the highest response rate with TPT was 10% in a phase II trial that evaluated TPT on a cumbersome 21-day continuous infusion schedule in previously untreated patients with advanced colorectal carcinoma [16] . In addition, a low level of objective activity in patients with advanced colorectal carcinoma has been observed in phase I studies despite treatment of a significant proportion of such patients with TPT at doses approaching the MTD [22, 23, [25] [26] [27] [28] [29] . One of the few major responses seen in patients with advanced colorectal carcinoma in phase I evaluations occurred in a patient with fluorpyrimidine-refractory disease who was treated with high doses of TPT (3.5 mg/m 2 /day for five days with G-CSF) in a phase I study that served, in part, as the impetus for the present study [22] .
The rationale for this phase II study of high-dose TPT with G-CSF support was based on the hypothesis that the low clinical activity of TPT against colorectal carcinoma and other malignancies in which MDR is presumed to play an important role in conferring drug resistance might be overcome by administering moderately higher doses of TPT. However, it should be realized that duration of drug exposure, and not drug dose or concentration, is the most important determinant of drug effect in preclinical studies [1] . In addition, although such reasoning regarding the potential for higher doses to overcome MDR has not resulted in a significant advantage for other agents that are substrates for Pgp in tumor types derived from tissues that constituitively overexpress Mdr, the demonstration that Pgp overexpression confers only a low magnitude of crossresistance to TPT in vitro suggested that the situation might be different for TPT. Indeed, a phase I and pharmcological study of TPT with G-CSF support demonstrated that a 2.3-fold dose escalation of TPT to 3.5 mg/m 2 /day as a 30-minute infusion daily for five days was feasible in patients with excellent performance status and minimal prior treatment defined in an identical manner as the present study [33] . At the recommended phase II dose, 3.5 mg/m 2 /day, respective mean AUC values for total TPT and lactone were demonstrated to be 2.2-and 2.3-fold higher than those achieved at the 2.0 mg/m 2 /day dose level. However, the substantial interpatient variability with TPT as demonstrated in the present study and in other trials may result in a substantial overlap in both AUC and C max values achieved with standard and high TPT doses and may confound the interpretation of evaluations of high-dose therapy. Except for alkylating agents and several anti-tumor antibiotics, drugs that belong to only a few classes of antitumor agents have been able to be dose-escalated to this extent in conjunction with hematopoietic growth factors. Nevertheless, the lack of major activity in this phase II study demonstrated that these efforts were to little avail.
The rates of severe toxicities in the present phase II study of high-dose TPT with G-CSF support were much higher than those reported in the phase I study from which the recommended doses were based. At the 3.5 mg/m 2 /day dose level in the phase I study, no patient experienced an ANC <500/ul lasting longer than five days and platelet counts < 25,000/ ul occurred in three of seven patients during four of 18 courses. However, at the same dose level in the present study, seven of 17 patients experienced ANC < 500/ul for longer than five days, seven patients developed fever associated with severe neutropenia, and nine patients developed grade 4 thrombocytopenia. In the phase I study, no patient who was initially treated at the 3.5 mg/m 2 /day dose level required a dose reduction, whereas TPT doses had to be reduced in seven of 17 patients due to severe toxicity in the phase II study. These substantial toxicological differences were noted despite the treatment of patients with similar performance status and extent of prior myelosuppressive therapies. Both studies were very restrictive with respect to the extent of prior myelosuppressive chemotherapy and radiotherapy. Patients who received limited radiotherapy did not have a higher propensity to develop severe hematologic toxicity than patients who had no prior radiotherapy.
One possible explanation for the considerable differences in the severity of myelosuppressive effects between patients participating in this phase II study and the phase I study of TPT/G-CSF from which the recommended dose of TPT/G-CSF was derived is that substantially greater total TPT AUCs were achieved in the phase II study than in the phase I study at the TPT 3.5 mg/m 2 /day dose level (mean 42 uM/h, range 26-109; versus mean 19 uM/h, range 6.5-32; P = 0.003, Wilcoxon rank sum test). This is particularly intriguing since the patients who participated in both studies were identical with respect to estimates of renal function, performance status, extent of prior therapy, and nearly identical with regard to tumor type. General differences between studies in concurrent medications, particularly those that might affect TPT clearance and hepatic excretion, must also be considered. For example, probenecid has been demonstrated to increase TPT exposure, most likely due to inhibition of renal tubular secretion of TPT's hydroxy acid species [30] . However, there is no evidence for general differences in concurrent medication use (e.g., probenecid and weak acids) between the two studies. Alternatively, renal secretory elimination mechanisms may be saturated at high TPT doses. It is also possible that a compensatory increase in hepatic excretion of TPT may occur when renal secretion is saturated. Patients in the present study had higher baseline total bilirubin values than those in the phase I study from which the dose used in the present study was derived (median 0.7, range 0.3-1.8; versus median 0.3, range 0.3-1.0; P = 0.064, Wilcoxan rank sum test), which may explain, in part, the differences in drug clearance between these two studies. In addition, there was a trend for higher AUC values with increasing bilirubin concentrations for patients treated with TPT 3.5 mg/m 2 /day in both studies (r = 0.55, P = 0.02).
The nonhematological effects of high-dose TPT occurred more frequently compared to those associated with lower doses; however, severe nonhematological toxicities occurred during only five of 89 (5.6%) courses. Interestingly, headache was experienced during 21 (23.5%) and severe headache accounted for four of the five episodes of severe toxic events. One potential explanation for the relatively high rate of several of these toxicities, particularly headache and malaise and possibly nausea and vomiting, is the known ability of TPT to cross the blood-brain barrier into the cerebrospinal fluid and the central nervous system [31, 32] .
Although the results of the present study indicate that the true response rate of high-dose TPT with G-CSF support is not likely to be 20% or greater in patients with advanced colorectal cancer that is refractory to the fluoropyrimidines, the present study results did not rule out the possibility that the true response rate of high dose TPT is less than 20% with acceptable statistical certainty (^ 5% probability of incorrectly rejecting the treatment). To demonstrate that a true response rate of high-dose TPT lower than 20% might exist with an acceptable level of statistical confidence, treatment of a larger number of additional patients would be required. In addition, other new antineoplastic agents such as irinotecan in colorectal cancer, TPT in ovarian cancer, and gemcitabine in pancreatic cancer have objective response rates lower than 20% [7, [13] [14] [15] [16] [17] 33 ], yet these therapies are associated with additional clinical advantages such as acceptable toxicity profiles and/or a relatively high rate of objective symptomatic benefit in patients who experience less than a major objective response. The substantial toxicities, inconvenience, and cost associated with this high-dose TPT regimen and the requirement for hematopoietic colony-stimulating factor support do not warrant acceptance of a lower level of antitumor activity (response rate < 20%) as a criterion for further developing this high-dose TPT/G-CSF regimen for colorectal cancer.
